EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA

Sujoy Ghosh iD, Pradip Mukhopadhyay, Prabhakar Pandey, Purushottam Chatterjee, Kaushik Pandit

Diabetes and Vascular Disease Research · 2020-11 · 17 (6)

DOI: 10.1177/1479164120973653 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes and Vascular Disease Research, online erschienen am 20.11.2020. Verfasst von Sujoy Ghosh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, India. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite having unquestionable glucose lowering efficacy, current guidelines no more favour the uses of sulphonylureas for CV safety concern, except when cost is an issue. However, formal cardiovascular outcome trial (CVOT) is not available. Materials and methods: We performed an indirect treatment comparison to find the hazard ratio for 3-point MACE, all-cause death, CV death and non-CV death between glimepiride and placebo based on two large CVOTs which established the CV safety of linagliptin (CARMELINA and CAROLINA).

Results

Glimepiride was shown to have a non-inferior risk compared to placebo for 3-point MACE (HR 1.04, 95% CI 0.850, 1.274), all-cause mortality (HR 1.08, 95% CI 0.880, 1.317), CV death (HR 0.96, 95% CI 0.732, 1.259), and non-CV death (HR 1.24, 95% CI 0.893, 1.733).

Conclusion

Cardiovascular safety of glimepiride is re-assuring and may help patients with type 2 diabetes world-over to avail the benefit of this affordable efficacious medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesClinical Trials as TopicDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsEvidence-Based MedicineHeart Disease Risk FactorsHumansHypoglycemic AgentsLinagliptinRisk AssessmentSulfonylurea CompoundsTreatment Outcome

Stichwörter der Autor:innen

CARMELINACAROLINACardiovascular safetyglimipiride

Substanzen

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsSulfonylurea CompoundsLinagliptinglimepiride

Autor:innen und Institutionen

  • Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, India.
  • Department of Pharmacy, RV Northland Institute, Greater Noida, UP, India.
  • Department of Endocrinology, Apollo Gleaneagles Hospital, Kolkata, West Bengal, India.

ORCID-Profile: Sujoy Ghosh

Zitieren

APA

Ghosh, S., Mukhopadhyay, P., Pandey, P., Chatterjee, P., & Pandit, K. (2020). Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA. Diabetes and Vascular Disease Research, 17(6). https://doi.org/10.1177/1479164120973653

Vancouver

Ghosh S, Mukhopadhyay P, Pandey P, Chatterjee P, Pandit K. Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA. Diabetes and Vascular Disease Research. 2020;17(6). doi:10.1177/1479164120973653

BibTeX
@article{Ghosh2020,
  author = {Ghosh, Sujoy and Mukhopadhyay, Pradip and Pandey, Prabhakar and Chatterjee, Purushottam and Pandit, Kaushik},
  title = {Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA},
  journal = {Diabetes and Vascular Disease Research},
  year = {2020},
  volume = {17},
  number = {6},
  doi = {10.1177/1479164120973653}
}
Kostenlos starten →